Register for IPO Updates
US IPO Stats
IPO Industry Breakdown
Largest Global IPOs
Largest US IPOs
IPO News Archive
New Ways to Invest in IPOs - IPO ETFs
US IPO Weekly Recap: Only five deals get done after massive valuation cuts
Analyst IPO Market Commentary
Home, home below the range: all five deals this week priced below the range.
There were eleven companies on the IPO
this week, but only five were
able to price
, and each of those priced at least 19% below their proposed midpoints. Furthermore, these 5 IPOs had a somewhat underwhelming performance, posting an average first-day pop of -2.2%. Total returns were better (10.2% average) thanks to Edge Therapeutics' strong aftermarket trading (+35.1%).
Of the seven health care companies that were expected to price, only four did. The three that didn’t, Cerecor (
), SynCardia Systems (
) and Strongbridge Biopharma (
), were likely victims of the fast-falling biotech market. The Nasdaq Biotech Index (Nasdaq: NBI) is down 15% in the last three months and 62% of health care companies to go public in 2015 are now trading below their IPO price, which is approximately in line with the IPO market overall. There were also three microcap Chinese manufacturers, Sole Elite Group (
), Fuling Global (
) and Boxlight (
), on the calendar that failed to get done.
A poor performance
This week had the first offerings from big LBOs from the pre-recession buyout boom. Performance Food Group (
) was the largest deal of the week and the fourth largest consumer IPO of 2015, even after pricing its $276 million IPO well below its range. The third-largest US foodservice distributor offered 14.5 million shares (12% insider) at $19 ($22-$25 range). Despite that it is faster growing than its peers, investors may have been concerned with its below average margins and high leverage (3.7x LTM EBITDA; B1/B rated debt).
Massive cuts for Surgery Partners
Surgery Partners (
), which owns or operates 99 surgical facilities in the US, had the second largest IPO this week, raising $271 million, which gave it a market cap of $914 million. It traded down 5% in its debut, but recovered slightly to end the week down 3%. Investors may have pushed for an in-line valuation given its high, variable-rate debt, uncertainty around the integration of the Symbion acquisition and recent volatility in the health care space.
Investors on Edge
Edge Therapeutics (
) had the strongest returns this week, popping 18% in its first day and ending the week up 59%. However, Edge priced 27% below its range and raised $80 million at a market cap of $332 million, a 24% discount to the originally proposed valuation. Backed by NEA, Sofinnova, Pfizer and Celgene, Mirna Therapeutics (
) went public at $7, 50% below its proposed range of $13-$15. It ended the week trading at $7.04, a return of just 0.6%. The company raised $44 million at a market cap of $142 million (41% discount).
The last IPO of the week, Novocure (
), cut its price range and removed insider selling on Thursday. On Friday, it priced below the downwardly-revised range and below its last venture round ($23.33 per share), then traded down 17%. It raised $165 million at a market cap of $2.1 billion. This poor showing came just two weeks after Penumbra (
), another medical products company, went public.
5 IPOs during the week of September 28, 2015
Deal size ($mm)
IPO price vs. midpoint
Return at 10/02
Edge Therapeutics (
Biotech: Brain aneurysms
Performance Food Group (
Mirna Therapeutics (
Biotech: microRNA cancer therapy
Surgery Partners (
Surgical facility operator
Biotech: Brain cancer device
Find out why institutional investors rely on Renaissance Capital's
for these IPOs.
Follow us on Twitter (
) for IPO news as it happens and
register for our updates
on the IPO market.
IPO Market Snapshot
Strong IPO volume in the fourth quarter will in part hinge on improved returns for recent IPOs. The Renaissance IPO Index has traded down 10.2% year-to-date, compared to -5.2% for the S&P 500. Renaissance Capital's
(NYSE: IPO) tracks the index, and
top ETF holdings
include Alibaba (
), Hilton Worldwide (
) and Twitter (
). The Renaissance International IPO Index has traded down 5.2% year-to-date, compared to -7.2% for the ACWX. Renaissance Capital’s International
(NYSE: IPOS) tracks the index, and
top ETF Holdings
include Recruit Holdings and Cheil Industries.
To find out if this is the best ETF for you, visit our
IPO Investing page
Keywords / Tickers: CERCU,
Recently Priced IPOs
ETF Express Award:
ETFExpress awards are based on a 'peer review system' whereby readers - including institutional and high net worth investors as well as managers and other industry professionals at fund administrators, brokers, custodians and advisers - are invited to elect a 'best in class' in a series of categories via an online survey. In each category, the firms with the most votes at the end of the voting period are subject to a final review by ETFExpress's Senior Editorial team.
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.
As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund's average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees.
An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.
Definitions: Net Asset Value (NAV) of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding. Market Price is current value at which an asset or service can be bought or sold. Premium/Discount is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds.
Renaissance IPO Index® (IPOUSA)
is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios.
Renaissance International IPO Index® (IPOXUS)
is a stock market index based upon a portfolio of newly public companies listed on non-U.S. exchanges.
The S&P 500® Index (SPX) is a stock market index which includes 500 U.S. listed companies and seeks to capture approximately 80% coverage of available U.S. market capitalization.
Risk Disclosure: Investments in the
Renaissance IPO ETF, symbol "IPO"
Renaissance International IPO ETF, symbol "IPOS"
(the "ETFs"), and the
Global IPO Fund, symbol "IPOSX"
(the "Mutual Fund") are subject to investment risk, including possible loss of the principal amounts invested. The ETFs and the Mutual Fund (the "Funds") invest in companies that have recently completed initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. Due to a greater number of IPOs in certain segments, the Funds may also be subject to information technology and financial sector risk, small and mid-capitalization company risk, and, for the Renaissance International IPO ETF, emerging markets risk. The Funds may hold securities in the form of Depository Receipts, REITs, and Partnership Units which have greater risks than common shares. The strategies have high portfolio turnover and securities lending risks. The returns of the ETFs may not match the return of the respective indices. The ETFs are classified as non-diversified investment companies subject to concentration risk.
Prospectus: Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with this and other information, please visit
. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETFs, 1-866-486-6645.
Definitions: The Renaissance IPO Index® is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The S&P 500® Index is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE or Nasdaq.
The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital - manager of IPO-focused ETFs.
The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO), the Renaissance International IPO ETF (symbol: IPOS), or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.
Register for Updates
Renaissance Capital LLC is an SEC-registered investment adviser.
Renaissance Capital Investments, Inc. is a
-registered broker-dealer, and member of
© 2016 Renaissance Capital LLC. All rights reserved.